期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 24, 页码 -出版社
MDPI
DOI: 10.3390/ijms232416116
关键词
niclosamide; FDA-approved drug; pharmacological activity; therapeutic prospect; cancer; disease
资金
- National Natural Science Foundation of China
- [81828009]
- [81572611]
Niclosamide is an FDA-approved anthelmintic drug, but recent studies have shown that it has potential therapeutic benefits beyond treating parasitic infections. It has shown promising results in treating metabolic diseases, immune system diseases, bacterial and viral infections, asthma, arterial constriction, myopia, and cancer. Niclosamide could be a valuable therapeutic option for various human diseases and cancer.
Niclosamide is an FDA-approved anthelmintic drug for the treatment of parasitic infections. However, over the past few years, increasing evidence has shown that niclosamide could treat diseases beyond parasitic diseases, which include metabolic diseases, immune system diseases, bacterial and viral infections, asthma, arterial constriction, myopia, and cancer. Therefore, we systematically reviewed the pharmacological activities and therapeutic prospects of niclosamide in human disease and cancer and summarized the related molecular mechanisms and signaling pathways, indicating that niclosamide is a promising therapeutic player in various human diseases, including cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据